Show simple item record

dc.contributor.authorNnate, Daniel A.
dc.contributor.authorMabhala, Mzwandile A.
dc.contributor.authorMassey, Alan
dc.date.accessioned2020-11-04T14:14:23Z
dc.date.available2020-11-04T14:14:23Z
dc.identifierhttps://chesterrep.openrepository.com/bitstream/handle/10034/623926/PRO19-00290-protocol_Revised.pdf?sequence=6
dc.identifier.citationNnate, D.A., Mabhala, M. & Massey, A. (2020). Effectiveness of nitric oxide agents in preventing the early onset of pre-eclampsia and possible modification of metabolic factors in high-risk pregnancies. JBI Evidence Synthesis. doi: 10.11124/JBISRIR-D-19-00290en_US
dc.identifier.urihttp://hdl.handle.net/10034/623926
dc.description.abstractObjectives: To determine the effectiveness of nitric oxide agents in modifying the metabolic factors of pre-eclampsia and its effectiveness in preventing the onset of pre-eclampsia in high-risk pregnancies. Introduction: Pre-eclampsia is a major cause of maternal death during the prenatal and neonatal periods. Nitric oxide is a vasodilator and platelet aggregation inhibitor responsible for the vascular adaptation of the placenta. Although various studies have established that nitric oxide is effective in preventing complications from pre-eclampsia, there is limited evidence to show that administering nitric oxide agents to the high-risk women before 20 weeks’ gestation will prevent the onset of pre-eclampsia. Inclusion criteria: This review will consider randomized controlled trials that compare nitric oxide donors and precursors with a placebo or no intervention on pregnant women (18 to 44 years) with ≤ 20-week gestational age that are at high risk of pre-eclampsia. The primary outcome of interest will be the onset of pre-eclampsia. Secondary outcomes include increased systolic and diastolic blood pressure, elevated asymmetric dimethylarginine levels, decreased endothelial nitric oxide synthase activity, reduced maternal placental vasculature, and abnormal Doppler ultrasound waveforms. Methods: Data sources will be drawn up from MEDLINE, CINAHL, ProQuest (Health and Medicine) and Web of Science from inception till current date. No language restrictions will be applied in the search strategy. Selected studies will be assessed against the JBI critical appraisal checklist, and the certainty of evidence and strength of recommendations from findings will also be ascertained. Systematic review registration number: CRD42018099298en_US
dc.publisherJoanna Briggs Institute (Wolters Kluwer Health, Inc.)en_US
dc.relation.urlhttps://journals.lww.com/jbisrir/Abstract/9000/Effectiveness_of_nitric_oxide_agents_in_preventing.99861.aspxen_US
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/en_US
dc.subjectAsymmetric dimethylarginineen_US
dc.subjecthigh-risk pregnancyen_US
dc.subjectnitric oxideen_US
dc.subjectplacental growth factoren_US
dc.subjectpre-eclampsiaen_US
dc.titlePublication Preview Source Effectiveness of nitric oxide agents in preventing the early onset of pre-eclampsia and possible modification of metabolic factors in high-risk pregnancies: a systematic review protocolen_US
dc.title.alternativeEffectiveness of nitric oxide agents in preventing the early onset of pre-eclampsia and possible modification of metabolic factors in high-risk pregnancies:en_US
dc.typeArticleen_US
dc.identifier.eissn2689-8381en_US
dc.contributor.departmentUniversity of Chesteren_US
dc.identifier.journalJBI Evidence Synthesisen_US
or.grant.openaccessYesen_US
rioxxterms.funderunfundeden_US
rioxxterms.identifier.projectunfundeden_US
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.11124/JBISRIR-D-19-00290en_US
rioxxterms.licenseref.startdate2020-03-29
rioxxterms.publicationdate2020-07-03
dc.dateAccepted2020-03-29
dc.date.deposited04-11-2020en_US


Files in this item

Thumbnail
Name:
PRO19-00290-protocol_Revised.pdf
Size:
223.9Kb
Format:
PDF
Request:
Main article

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International